<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2680919-A2" country="EP" doc-number="2680919" kind="A2" date="20140108" family-id="46719478" file-reference-id="276026" date-produced="20180825" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146587369" ucid="EP-2680919-A2"><document-id><country>EP</country><doc-number>2680919</doc-number><kind>A2</kind><date>20140108</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-12752621-A" is-representative="NO"><document-id mxw-id="PAPP154849561" load-source="docdb" format="epo"><country>EP</country><doc-number>12752621</doc-number><kind>A</kind><date>20120228</date><lang>EN</lang></document-id><document-id mxw-id="PAPP172244784" load-source="docdb" format="original"><country>EP</country><doc-number>12752621.8</doc-number><date>20120228</date></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140550819" ucid="US-201113037171-A" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>201113037171</doc-number><kind>A</kind><date>20110228</date></document-id></priority-claim><priority-claim mxw-id="PPC140553384" ucid="US-2012027021-W" linkage-type="W" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>2012027021</doc-number><kind>W</kind><date>20120228</date></document-id></priority-claim></priority-claims><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL-1946289384" load-source="docdb">C12N  13/00        20060101ALI20160415BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1946289385" load-source="docdb">C12N   5/071       20100101ALI20160415BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1946289386" load-source="docdb">B82Y   5/00        20110101ALN20160415BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1946289387" load-source="docdb">A61P  37/04        20060101ALI20160415BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1946289388" load-source="docdb">A61M  37/00        20060101ALI20160415BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1946289389" load-source="docdb">A61K  41/00        20060101ALI20160415BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1946289390" load-source="docdb">A61K  39/39        20060101ALI20160415BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1946289391" load-source="docdb">A61K   9/00        20060101ALI20160415BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1946289392" load-source="docdb">A61K  47/48        20060101AFI20160415BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1946289393" load-source="docdb">A61P  35/00        20060101ALI20160415BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL-1777723572" load-source="docdb" scheme="CPC">A61K  47/6925      20170801 LI20170802BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1777723573" load-source="docdb" scheme="CPC">A61K  47/61        20170801 LI20170802BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1953522966" load-source="docdb" scheme="CPC">B82Y   5/00        20130101 LA20130709BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2062985692" load-source="docdb" scheme="CPC">C12N2533/30        20130101 LA20150425BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2062988872" load-source="docdb" scheme="CPC">A61K2039/6087      20130101 LA20150425BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2062990600" load-source="docdb" scheme="CPC">A61K2039/55583     20130101 LA20150425BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2062991939" load-source="docdb" scheme="CPC">C12N   5/0068      20130101 LI20150425BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2062992601" load-source="docdb" scheme="CPC">A61K  39/0011      20130101 LI20150425BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2062993060" load-source="docdb" scheme="CPC">A61K  41/0052      20130101 LI20150425BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989622553" load-source="docdb" scheme="CPC">Y10S 977/918       20130101 LA20130627BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989624463" load-source="docdb" scheme="CPC">A61N   5/062       20130101 LI20130627BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989627990" load-source="docdb" scheme="CPC">A61K  41/0057      20130101 FI20130709BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989652149" load-source="docdb" scheme="CPC">Y10S 977/746       20130101 LA20130627BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132366740" lang="DE" load-source="patent-office">IMMUNOLOGISCH MODIFIZIERTE KOHLENSTOFFNANORÖHRCHEN ZUR KREBSBEHANDLUNG</invention-title><invention-title mxw-id="PT132366741" lang="EN" load-source="patent-office">IMMUNOLOGICALLY MODIFIED CARBON NANOTUBES FOR CANCER TREATMENT</invention-title><invention-title mxw-id="PT132366742" lang="FR" load-source="patent-office">NANOTUBES DE CARBONE IMMUNOLOGIQUEMENT MODIFIÉS POUR LE TRAITEMENT DU CANCER</invention-title></technical-data><parties><applicants><applicant mxw-id="PPAR919517499" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>UNIV CENTRAL OKLAHOMA</last-name><address><country>US</country></address></addressbook></applicant><applicant mxw-id="PPAR919518617" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>THE UNIVERSITY OF CENTRAL OKLAHOMA</last-name></addressbook></applicant><applicant mxw-id="PPAR919011950" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>The University of Central Oklahoma</last-name><iid>101335497</iid><address><street>Center For Transformative Learning Room 205</street><city>Edmond, OK 73034</city><country>US</country></address></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR919526174" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>CHEN WEI R</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919510019" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>CHEN, WEI, R.</last-name></addressbook></inventor><inventor mxw-id="PPAR919015893" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>CHEN, WEI, R.</last-name><address><street>1305 NW 195th Street</street><city>Edmond, OK 73012</city><country>US</country></address></addressbook></inventor></inventors><agents><agent mxw-id="PPAR919019704" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Leppard, Andrew John</last-name><suffix>et al</suffix><iid>101333275</iid><address><street>Script IP Limited Turnpike House 18 Bridge Street Frome</street><city>Somerset BA11 1BB</city><country>GB</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="US-2012027021-W"><document-id><country>US</country><doc-number>2012027021</doc-number><kind>W</kind><date>20120228</date><lang>EN</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2012118857-A2"><document-id><country>WO</country><doc-number>2012118857</doc-number><kind>A2</kind><date>20120907</date><lang>EN</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS549919308" load-source="docdb">AL</country><country mxw-id="DS549772189" load-source="docdb">AT</country><country mxw-id="DS549919309" load-source="docdb">BE</country><country mxw-id="DS549854965" load-source="docdb">BG</country><country mxw-id="DS549856873" load-source="docdb">CH</country><country mxw-id="DS549786596" load-source="docdb">CY</country><country mxw-id="DS549772190" load-source="docdb">CZ</country><country mxw-id="DS549919310" load-source="docdb">DE</country><country mxw-id="DS549786625" load-source="docdb">DK</country><country mxw-id="DS549786626" load-source="docdb">EE</country><country mxw-id="DS549856403" load-source="docdb">ES</country><country mxw-id="DS549854974" load-source="docdb">FI</country><country mxw-id="DS549874002" load-source="docdb">FR</country><country mxw-id="DS549919311" load-source="docdb">GB</country><country mxw-id="DS549786627" load-source="docdb">GR</country><country mxw-id="DS549919312" load-source="docdb">HR</country><country mxw-id="DS549772191" load-source="docdb">HU</country><country mxw-id="DS549856878" load-source="docdb">IE</country><country mxw-id="DS549786628" load-source="docdb">IS</country><country mxw-id="DS549874003" load-source="docdb">IT</country><country mxw-id="DS549786641" load-source="docdb">LI</country><country mxw-id="DS549854975" load-source="docdb">LT</country><country mxw-id="DS549772561" load-source="docdb">LU</country><country mxw-id="DS549854976" load-source="docdb">LV</country><country mxw-id="DS549854977" load-source="docdb">MC</country><country mxw-id="DS549772562" load-source="docdb">MK</country><country mxw-id="DS549772563" load-source="docdb">MT</country><country mxw-id="DS549772192" load-source="docdb">NL</country><country mxw-id="DS549856404" load-source="docdb">NO</country><country mxw-id="DS549856879" load-source="docdb">PL</country><country mxw-id="DS549854982" load-source="docdb">PT</country><country mxw-id="DS549772205" load-source="docdb">RO</country><country mxw-id="DS549854983" load-source="docdb">RS</country><country mxw-id="DS549856880" load-source="docdb">SE</country><country mxw-id="DS549874004" load-source="docdb">SI</country><country mxw-id="DS549856405" load-source="docdb">SK</country><country mxw-id="DS549856881" load-source="docdb">SM</country><country mxw-id="DS549772564" load-source="docdb">TR</country></ep-contracting-states></designated-states></international-convention-data><office-specific-data><eptags><ep-no-a-document-published>*</ep-no-a-document-published></eptags></office-specific-data></bibliographic-data><abstract mxw-id="PA99832425" ref-ucid="WO-2012118857-A2" lang="EN" load-source="patent-office"><p num="0000">A method for constructing a compound of immunologically modified nanotubes and method for using the compound to deliver immunoadjuvants to tumor cells and to produce targeted, synergistic photophysical and immunological reactions for cancer treatment. To prepare the immunologically modified nanotubes, carbon nanotubes are dissolved in a solution of glycated chitosan, an immunostimulant, hence using glycated chitosan as a surfactant for rendering the aqueous solution of nanotubes stable. The compound can be used for treatment of cancer. The method includes steps of intratumorally administering immunologically modified nanotubes and administering laser irradiation of the target tumor. The nanotube serves as a carrier to deliver immunoadjuvants to the tumor cells and serves as a light-absorbing agent in a cell body of a tumor in a host. Upon laser irradiation of target tumor cells, immunologically modified nanotubes inside the tumor cells can produce spatially and temporally synchronized photothermal and immunological reactions for cancer treatment.</p></abstract><abstract mxw-id="PA100329049" ref-ucid="WO-2012118857-A2" lang="EN" source="national office" load-source="docdb"><p>A method for constructing a compound of immunologically modified nanotubes and method for using the compound to deliver immunoadjuvants to tumor cells and to produce targeted, synergistic photophysical and immunological reactions for cancer treatment. To prepare the immunologically modified nanotubes, carbon nanotubes are dissolved in a solution of glycated chitosan, an immunostimulant, hence using glycated chitosan as a surfactant for rendering the aqueous solution of nanotubes stable. The compound can be used for treatment of cancer. The method includes steps of intratumorally administering immunologically modified nanotubes and administering laser irradiation of the target tumor. The nanotube serves as a carrier to deliver immunoadjuvants to the tumor cells and serves as a light-absorbing agent in a cell body of a tumor in a host. Upon laser irradiation of target tumor cells, immunologically modified nanotubes inside the tumor cells can produce spatially and temporally synchronized photothermal and immunological reactions for cancer treatment.</p></abstract><abstract mxw-id="PA99832426" ref-ucid="WO-2012118857-A2" lang="FR" load-source="patent-office"><p num="0000">Cette invention concerne un procédé d'élaboration d'un composé constitué de nanotubes immunologiquement modifiés et une méthode d'utilisation dudit composé pour administrer des immunoadjuvants à des cellules tumorales et obtenir des réactions synergiques photophysiques et immunologiques ciblées pour traiter le cancer. Pour préparer les nanotubes immunologiquement modifiés selon l'invention, les nanotubes de carbone sont dissous dans une solution de chitosan glyqué, un immunostimulant, le chitosan glyqué étant de ce fait utilisé à titre de tensioactif pour stabiliser la solution aqueuse de nanotubes. Le composé peut être utilisé pour traiter le cancer. La méthode comprend les étapes consistant à administrer les nanotubes immunologiquement modifiés par voie intratumorale et à irradier la tumeur cible à l'aide d'un laser. Le nanotube sert de véhicule pour administrer les immunoadjuvants aux cellules tumorales et d'agent absorbant la lumière dans le corps cellulaire d'une tumeur chez un hôte. Lors de l'irradiation laser des cellules tumorales cibles, les nanotubes immunologiquement modifiés à l'intérieur des cellules tumorales peuvent induire des réactions photothermiques et immunologiques synchronisées dans l'espace et dans le temps pour traiter le cancer.</p></abstract><abstract mxw-id="PA100329050" ref-ucid="WO-2012118857-A2" lang="FR" source="national office" load-source="docdb"><p>Cette invention concerne un procédé d'élaboration d'un composé constitué de nanotubes immunologiquement modifiés et une méthode d'utilisation dudit composé pour administrer des immunoadjuvants à des cellules tumorales et obtenir des réactions synergiques photophysiques et immunologiques ciblées pour traiter le cancer. Pour préparer les nanotubes immunologiquement modifiés selon l'invention, les nanotubes de carbone sont dissous dans une solution de chitosan glyqué, un immunostimulant, le chitosan glyqué étant de ce fait utilisé à titre de tensioactif pour stabiliser la solution aqueuse de nanotubes. Le composé peut être utilisé pour traiter le cancer. La méthode comprend les étapes consistant à administrer les nanotubes immunologiquement modifiés par voie intratumorale et à irradier la tumeur cible à l'aide d'un laser. Le nanotube sert de véhicule pour administrer les immunoadjuvants aux cellules tumorales et d'agent absorbant la lumière dans le corps cellulaire d'une tumeur chez un hôte. Lors de l'irradiation laser des cellules tumorales cibles, les nanotubes immunologiquement modifiés à l'intérieur des cellules tumorales peuvent induire des réactions photothermiques et immunologiques synchronisées dans l'espace et dans le temps pour traiter le cancer.</p></abstract><description mxw-id="PDES51232794" ref-ucid="WO-2012118857-A2" lang="EN" load-source="patent-office"><!-- EPO <DP n="2"/>--><p id="p0001" num="0001"> IMMUNOLOGICALLY MODIFIED CARBON NANOTUBES FOR CANCER </p><p id="p0002" num="0002"> TREATMENT </p><p id="p0003" num="0003">CROSS REFERENCE TO RELATED APPLICATION </p><p id="p0004" num="0004"> This application claims the benefit of U.S. Patent Application No. 13/037,171 filed February 28, 2011 , entitled, "IMMUNOLOGICALLY MODIFIED CARBON NANOTUBES FOR CANCER TREATMENT", herein incorporated by reference in its entirety for all purposes. </p><p id="p0005" num="0005"> FIELD OF THE INVENTION </p><p id="p0006" num="0006"> This invention is related to the field of biomedical applications of nanotechnology. More particularly, the invention is related to a new compound of immunologically modified carbon nanotubes and the use of the compound for delivering immunoadjuvants to tumor cells and for producing targeted, synergistic photophysical and immunological reactions for cancer treatment. </p><p id="p0007" num="0007"> BACKGROUND OF THE INVENTION </p><p id="p0008" num="0008"> Nanotechnology has been used in the biomedical fields. Specifically, single-walled carbon nanotubes (SWNTs) have been applied in various biological systems. One intrinsic property of SWNTs is their ability to cross cellular membranes without eliciting cytotoxicity. Another intrinsic properly of SWNTs is their strong optical absorbance in the near-infrared (NIR) region. It was reported that SWNTs could enhance thermal destruction of cells during NIR laser irradiation and radiofrequency irradiation. Since biological tissues are relatively transparent to light in the range of 700-1100 nm, the ideal SWNT for photothermal therapy should have an absorption band in the NIR region. Furthermore, it is desirable to have nanotubes with uniform size so that a narrow absorption peak can be used for effective optical irradiation. The CoMoCAT method, discussed in "Controlled production of single- wall 
<!-- EPO <DP n="3"/>-->
 carbon nanotubes by catalytic decomposition of CO on bimetallic Co-Mo catalysts" by Kitiyanan B, Alvarez WE, Harwell JH, Resasco DE (2000) in Chem. Phys. Lett. 317:497- 503, incorporated herein by reference, produces SWNTs with a narrow and intense absorption band around 980 nm. </p><p id="p0009" num="0009"> For biological applications, SWNTs should be prepared in aqueous suspension; surfactants are needed for stable dispersion to avoid aggregation of nanotubes. Sodium dodecylbenzene sulfonate (NaDDBS), sodium carboxymethylcellulose (NaCMC), and sodium cholate (NaCholate) are commonly used as surfactants for nanotubes. </p><p id="p0010" num="0010"> The electronic structure of SWNTs is sensitive to changes in the surrounding electrostatic environment. For example, their optical response can be greatly changed by surface charge transfers or by adsorption of molecules. Therefore, it is crucial to have a SWNT solution with appropriate optical properties for biomedical applications. </p><p id="p0011" num="0011"> Photothermal therapy can be effective for local cancer treatment due to the sensitivity of tumor cells to temperature elevation. Laser immunotherapy was developed to combine photothermal reaction with immunological stimulation to treat metastatic tumors. Its selective photothermal effect serves as the first line of assault on the tumor, using a combination of an NIR laser irradiation and a light-absorbing dye. An immunological stimulant is used concurrently to induce immunological responses. A new compound, glycated chitosan (GC), was developed as such an immunostimulant. Laser immunotherapy using GC and the light-absorbing dye has been proven to be highly effective in the treatment of metastatic tumors in pre-clinical studies. This method has also been used to treat late-stage breast cancer patients with promising outcomes. 
<!-- EPO <DP n="4"/>-->
 SUMMARY OF THE INVENTION </p><p id="p0012" num="0012"> Anti-tumor immunological response induced by local intervention is ideal for treatment of metastatic tumors. A novel immunologically modified nanotube system is constructed using glycated chitosan (GC), a potent immunoadjuvant, as an effective surfactant for single-walled carbon nanotubes (SWNTs). This novel SWNT-GC system has a long-term stability and it retains the absorption characteristics of SWNT and the immunological adjuvant function of GC. Locally administered SWNT-GC and irradiation of near-infrared light produced synergistic, simultaneous photothermal and immunological reactions in the treatment of tumor cells, both in vitro and in vivo. Laser+SWNT-GC resulted in highly effective tumor suppression in animal tumor models, with complete tumor regression and long-term survival in many cases. Tumor-bearing animals successfully treated with Laser+SWNT-GC established total resistance to subsequent tumor challenges. Passive adoptive immunity transfer using splenocytes as immune cells harvested from Laser+SWNT- GC-cured animals provided 100% immunity in naive recipients. Laser+SWNT-GC could prove to be a promising selective local treatment modality that induces systemic anti-tumor response, while minimizing adverse side effects. </p><p id="p0013" num="0013"> To utilize the special absorption properties of the CoMoCAT SWNTs, and to immunologically enhance photothermal effects, a novel SWNT-GC system was designed in which GC simultaneously serves as an effective surfactant and a potent immunostimulant, providing two crucial functionalities to this novel system. SWNT-GC suspension is stable and it completely retains the light absorption characteristics of SWNTs and the immunological functions of GC. Using local laser+SWNT-GC treatment has resulted in significant tumor suppression and anti-tumor immunological responses in animal tumor models. 
<!-- EPO <DP n="5"/>-->
 Furthermore, nanotubes can enter cells due to their size and electric properties. Nanotubes can serve as drug carriers. In the method of this invention, nanotubes carry the immunoadjuvant, GC, into the tumor cells. Therefore, under irradiation of a laser light of appropriate wavelength, SWNT-GC can produce temporally and spatially synchronized photothermal and immunological reactions in the target tumor cells. The SWNT-GC combination also has the potential to carry other therapeutic agents to tumors so that cancer can be treated with combination therapy of desired agents. 
<!-- EPO <DP n="6"/>-->
</p><p id="p0014" num="0014">BRIEF DESCRIPTION OF THE DRAWINGS </p><p id="p0015" num="0015"> Figure 1A. Schematic of the immunologically modified nanotube system, SWNT- GC. </p><p id="p0016" num="0016"> Figure I B. Absorption spectra of SWNT-GC suspension with different SWNT-GC concentrations (top curve, SWNT-GC concentration: 135 μg/ml-0.73 wt%; lower curves correspond to consecutive 50% reduction in SWNT-GC concentration). </p><p id="p0017" num="0017"> Figure 1 C. Raman spectra of SWNT-GC. </p><p id="p0018" num="0018"> Figure 2A. Selective photothermal effects using SWNT-GC and laser irradiation</p><p id="p0019" num="0019">(thermocouple measurement). Temperature inside gel phantoms (with or without nanotube enhancement) was measured by thermocouples during irradiation by a 980-nm laser. The laser power density was 1.13W/cm<sup>2</sup> and irradiation duration was 5 minutes. The thermocouples were placed 4 mm below the sample surfaces. </p><p id="p0020" num="0020"> Figure 2B. Selective photothermal effects using SWNT-GC and laser irradiation</p><p id="p0021" num="0021">(infrared thermal camera measurement). Temperature increase on the surface of gel phantoms (with or without nanotube enhancement) was measured during laser irradiations by an infrared thermal camera. The laser power density was 1.13W/cm<sup>2</sup> and irradiation duration was 5 minutes. </p><p id="p0022" num="0022"> Figure 3A. Temperature distribution in a gel phantom without nanotube enhancement before laser irradiation (magnetic resonance thermometry measurement). </p><p id="p0023" num="0023"> Figure 3B. Temperature distribution in a gel phantom without nanotube enhancement after laser irradiation (magnetic resonance thermometry measurement). The sample was irradiated by a 980-nm laser from the bottom. The power density was 0.212W/cm with a beam diameter of 3.0 cm. This figure shows the temperature distribution 7 minutes after laser radiation. 
<!-- EPO <DP n="7"/>-->
 Figure 3C. Temperature distribution in a gel phantom with nanotube enhancement before laser irradiation (magnetic resonance thermometry measurement). A nanotube enhanced spherical gel was buried 1 mm below the surface. </p><p id="p0024" num="0024"> Figure 3D. Temperature distribution in a gel phantom with nanotube enhancement after laser irradiation (magnetic resonsnce thermometry measurement). A nanotube enhanced spherical gel was buried 1 mm below the surface. The sample was irradiated by a 980-nm laser from the bottom. The power density was 0.212W/cm with a beam diameter of 3.0 cm. This figure shows the temperature distribution 7 minutes after laser radiation. </p><p id="p0025" num="0025"> Figure 4. Subcellular distribution of GC carried by SWNT and transported into the tumor cells. The fluorescence images of SWNT-GC-FITC (SWNT-GC conjugated to a fluorescent dye FITC) and GC-FITC (GC conjugated to a fluorescent dye FITC) in EMT6 cells were acquired. Cells were incubated with SWNT-GC-FITC and GC-FITC for 2 hours, and the fluorescence of FITC from cells was detected by laser scanning microscope. Note that GC could enter cells only when attached to SWNT. Bar=10 μιη. </p><p id="p0026" num="0026"> Figure 5. Viability of in vitro tumor cells under different treatments. Tumor cells were treated with GC (50 μ^νηΐ), SWNT-GC (2.5 μg-50 μξ/αύ), laser only (60, 120, or 150 J/cm<sup>2</sup>), or Laser+SWNT-GC (60, 120, or 150 J/cm<sup>2</sup>; 1.25 μg-25 μg /ml or 2.5 μ$-50 μg/ml). The treated cells were incubated in complete medium for 12 hours before assessing cell viability. Bars, means ± SD (n = 4). </p><p id="p0027" num="0027"> Figure 6A. In vitro immunological effects of SWNT-GC. TNFoc secretion by murine macrophages incubated with GC or SWNT-GC suspensions, detected by ELISA. Macrophages were incubated with GC solution of different concentrations (25, 50, and 90 μg/ml, gray bars) or with SWNT-GC solution of different concentrations (2.5 μg-25 μg, 2.5 
<!-- EPO <DP n="8"/>-->
 g-50 μg, and 2.5 μg-90 μg/ml, black bars) for 24 hours. After incubation, supematants were collected for the determination of TNFa. Bars, means ± SD (n = 4). </p><p id="p0028" num="0028"> Figure 6B. In vitro immunological effects of SWNT-GC: TNFa secretion by macrophages stimulated by treated EMT6 cells. Macrophages were incubated for 24 hours with tumor cells (1 : 1) treated by GC (50 g/ml), SWNT-GC (2.5 μg-50 μg/ml), laser light (60-150 J/cm<sup>2</sup>), or Laser+SWNT-GC (60-150 J/cm<sup>2</sup>, 2.5 μg-50 μ^πιΐ). Cells without treatment incubated with macrophages were used as control. After incubation, supematants were collected for the determination of TNFa. Bars, means ± SD (n = 4). </p><p id="p0029" num="0029"> Figure 7 A. Effects on tumor burden of intratumoral injections (at day 0) of different components: (i) control, (ii) SWNT (1 mg/kg), (iii) GC (25 mg/kg), or (iv) SWNT-GC (1 mg- 25 mg/kg); 12 mice/group. EMT6 cells were injected subcutaneously into the flanks of Balb/c female mice and treatment took place when tumors reached a size of approximately 300 nm<sup>3</sup>. </p><p id="p0030" num="0030"> Figure 7B. Effects on tumor burden of intratumoral injections of different components, followed by laser irradiation (0.75 W/cm for 10 minutes at day 0): (i) control, (ii) Laser, (iii) Laser+GC (25 mg/kg), (iv) Laser+SWNT (1 mg/kg), or (v) Laser+SWNT-GC (1 mg-25 mg/kg); 12 mice/group. EMT6 cells were injected subcutaneously into the flanks of Balb/c female mice and treatment took place when tumors reached a size of approximately 300 mm<sup>3</sup>. Laser+SWNT-GC and Laser+SWNT were significantly more efficacious in tumor reduction as compared with other groups. </p><p id="p0031" num="0031"> Figure 8A. In vivo effects of SWNT and GC without laser irradiation: Animal Survival. Survival rates of tumor-bearing mice treated by intratumoral injections (at day 0) of different components: (i) SWNT-GC (1 mg-25 mg/kg), (ii) GC (25 mg/kg), (iii) SWNT (1 mg/kg), or (iv) control: 12 mice/group. EMT6 cells were injected subcutaneously into the 
<!-- EPO <DP n="9"/>-->
 flanks of Balb/c female mice and treatment took place when tumors reached a size of approximately 300 mm<sup>3</sup>. </p><p id="p0032" num="0032"> Figure 8B. In vivo effects of SWNT and GC with laser irradiation: Animal Survival. Survival rates of tumor-bearing mice treated by intratumoral injections of different components, followed by laser irradiation (0.75 W/cm<sup>2</sup> for 10 minutes, day 0): (i) Laser+SWNT-GC (1 mg-25 mg.kg), (ii) Laser+SWNT (1 mg/.kg), (iii) Laser+GC (25 mg/kg), (iv) Laser, or (v) control; 12 mice/group. EMT6 cells were injected subcutaneously into the flanks of Balb/c female mice and treatment took place when tumors reached a size of approximately 300 mm<sup>3</sup>. Laser+SWNT-GC and Laser+SWNT were significantly more efficacious in animal survival as compared with other groups. </p><p id="p0033" num="0033"> Figure 9. Tumor rechallenge of successfully treated mice. Tumor-bearing mice cured by Laser+SWNT-GC or Laser+SWNT treatment were challenged with 2&gt; 10<sup>6</sup> viable tumor cells 100 days after the initial inoculation. Naive mice of the same age were also inoculated with 2* 10<sup>6</sup> viable tumor cells as controls. All the mice cured by Laser+SWNT-GC showed total resistance to the challenge; however, mice cured by laser+SWNT, while with a prolonged average survival time, were not completely refractory to the tumor rechallenge. </p><p id="p0034" num="0034"> Figure 10. Adoptive immunity using splenocytes as immune cells. Spleen cells from mice successfully treated by Laser+SWNT-GC or Laser+SWNT were collected as immune cells. Spleen cells from untreated tumor-bearing mice were also used as control immune cells. Viable tumor cells were admixed with spleen cells from different mice, then injected into naive mice. The spleen cell to tumor cell ratio was 50,000,000: 100,000 per mouse. The spleen cells from mice treated by Laser+SWNT-GC completely inhibited the tumor growth; all the mice in this group survived and none developed tumors. The spleen cells from 
<!-- EPO <DP n="10"/>-->
 Laser+SWNT-cured mice and control mice only provided 30% and 10% protections to the recipients, respectively. 
<!-- EPO <DP n="11"/>-->
</p><p id="p0035" num="0035">DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS MATERIALS AND METHODS </p><p id="p0036" num="0036"> CoMoCAT Single- Walled Carbon Nanotubes (SWNTs). </p><p id="p0037" num="0037"> The CoMoCAT SWNT is used due to its unique properties of uniform size and NIR light absorption. The CoMoCAT method produces single-walled carbon nanotubes using a silica supported bimetallic cobalt-molybdate catalyst. The product is composed of a narrow distribution of nanotube types, with an average diameter of 0.81 nm. This type of nanotube has been of interest due to its absorption characteristics in the near-infrared region, especially as it possesses an intense absorption band at approximately 980 nm. Nanotubes of this type are discussed in "Carbon nanotube-enhanced thermal destruction of cancer cells in a noninvasive radiofrequency field" by Gannon CJ, Cherukuri P, Yakobson BL, Cognet L, Kanzius JS, Kittrell C, Weisman RB, Pasquali M, Schmidt HK, Smalley RE, Curley SA (2007) in Cancer 1 10:2654-2665, "Multiphoton microscopy in life sciences" by Konig K (2000) in J. Microsc. (Oxford) 200:83-104, "Controlled production of single-wall carbon nanotubes by catalytic decomposition of CO on bimetallic Co-Mo catalysts" by Kitiyanan B, Alvarez WE, Harwell JH, Resasco DE (2000) in Chem. Phys. Lett. 317:497-503, and "Narrow (n,m)-distribution of single-walled carbon nanotubes grown using a solid supported catalyst" by Bachilo SM, Balzano L, Herrera JE, Pompeo F, Resasco DE, Weisman RB (2003) in J. Am. Chem. Soc. 125: 1 1 186-1 1187, each of which is hereby incorporated by reference. </p><p id="p0038" num="0038"> Glycated Chitosan (GC). </p><p id="p0039" num="0039"> GC is used as a special immunoadjuvant and as an effective surfactant for SWNT in this invention. GC was developed as an immunological stimulant for laser immunotherapy to treat metastatic tumors. GC is nontoxic in cell culture and in animal studies, as shown by 
<!-- EPO <DP n="12"/>-->
 previous experiments. GC may be synthesized by incubating an aqueous suspension of chitosan with a three-fold excess of galactose and subsequent stabilization by borohydride reduction of the mixture of Schiff bases and Amadori products as discussed in "Laser Immunotherapy: A Novel Treatment Modality for Metastatic Tumors" by Chen WR, Carubelli R, Liu H, Nordquist RE (2003) in Mol. Biotechnol. 25:37-43, hereby incorporated by reference. Examples of chitosan-derived biomaterials may be found in US Patent No. 5,747,475, the contents of which are hereby incorporated by reference. In addition to its immunodajuvant properties, the molecular structure of GC makes it a superb surfactant for SWNTs. </p><p id="p0040" num="0040"> Preparation for SWNT-GC and SWNT-PEG Solutions. </p><p id="p0041" num="0041"> CoMoCAT SWNT is used as an example of carbon nanotubes in this invention. Other nanostructures, such as nanoparticles, nanoclusters, and nanorods, can be used with GC to construct immunologically modified nanostructures. To prepare the SWNT-GC solution, pristine CoMoCAT SWNTs of 2.5-2.7 mg were mixed with 7-ml aqueous GC of different concentrations. It is contemplated that an amount within any subset of ranges within the range of 1 -5 mg will also be effective. To disperse the SWNTs, the mixture was sonicated for 30 minutes using an ultrasonic processor. This suspension of SWNTs was then centrifuged at 30,150g for 30 minutes. The final concentration of SWNT in GC solution was determined by comparing its optical absorbance with that of a calibration SWNT solution of known concentration. </p><p id="p0042" num="0042"> Optical Spectra Measurements. </p><p id="p0043" num="0043"> The optical absorbance of SWNT-GC was measured by a UV-vis absorption spectrophotometer. To take advantage of the intrinsic optical properties of SWNTs, Raman spectroscopy was used to verify the SWNT-GC conjugation using capillaries without 
<!-- EPO <DP n="13"/>-->
 spinning or stirring during the measurements. An argon ion laser (514.5 nm) was used for excitation in combination with a 40<sup>x</sup> objective of a microscope, a spectrometer, and a CCD detector. After focusing on the center of the capillary, the Raman spectrum of the sample was recorded with a resolution of 2 cm<sup>"1</sup> (10 mW power, 20 seconds collection time). </p><p id="p0044" num="0044"> Selective Photothermal Effects of Laser+SWNT-GC Using Gel Phantoms. </p><p id="p0045" num="0045"> SWNT with a 978 nm absorption peak was used for the SWNT-GC suspension. Gel phantom was mixed with SWNT-GC suspension to simulate absorption-enhanced targets. A 980-nm laser was used to irradiate both SWNT-GC gel samples and normal gel samples. Temperature increases at a depth of 4 mm below the gel surface was measured by thermocouples. The surface temperatures of gel phantoms with and without SWNT-GC enhancement during laser irradiation were measured using an infrared thermal camera. </p><p id="p0046" num="0046"> Using a magnetic resonance imager, the temperature distribution inside a gel phantom during laser irradiation was measured. The gelatin gel was placed in a cylinder container. The temperature distributions inside a normal gel block, before and during laser irradiation were also measured. To enhance the gel absorption, a gel sphere of 0.5-cm radius containing SWNT-GC suspension was imbedded in the gel 1 mm beneath the surface to simulate a deep target tumor. The temperature distribution inside the SWNT-GC enhanced gel block, before and during laser irradiation, were measured. </p><p id="p0047" num="0047"> Cell Culture. </p><p id="p0048" num="0048"> Murine mammary tumor line EMT6 cells and murine macrophage line RAW264.7 cells were used in the experiments. The cells were cultured in RPMI 1640 (GIBCO) supplemented with 15% fetal calf serum (FCS), penicillin (100 units/ml), and streptomycin (100 μ^ητΐ) in 5% C0<sub>2</sub>, 95% air at 37°C in an humidified incubator. 
<!-- EPO <DP n="14"/>-->
 GC-FITC and SWNT-GC-FITC Functionalization. </p><p id="p0049" num="0049"> FITC (13 mM, 50 μΐ) was dissolved in DMSO, and then mixed with 1 ml GC or SWNT-GC solutions. After incubating the mixture for overnight at room temperature, avoiding light exposure, the GC-FITC or SWNT-GC-FITC solutions were filtrated through 100 KDa filters (Millipore) to remove excess FITC. Then GC-FITC and SWNT-GC-FITC were incubated with EMT6 tumor cells for 2 hours and the fluorescence of FITC from the cells was detected using laser scanning microscope. </p><p id="p0050" num="0050"> Cell Viability Assays. </p><p id="p0051" num="0051"> Tumor cells (1 x 104 per well) in 24- well tissue culture plates were incubated with different combinations of SWNT and GC for 2 hours, rinsed with PBS, and exposed to light at a fluence of 60-150 J/cm<sup>2</sup> (0.5-1.25 W/cm<sup>2</sup> for 2 min). The light source was a 980-nm semiconductor laser. </p><p id="p0052" num="0052"> Cell cytotoxicity in vitro was performed with a colorimetric tetrazolium salt-based assay, Cell Counting Kit-8 (CCK8). To detect photothermal cytotoxicity, tumor cells were irradiated by a 980-nm laser with or without incubation with SWNT-GC. OD450, the absorbance value at 450 nm, was read with a 96- well plate reader, to determine the viability of the cells. </p><p id="p0053" num="0053"> Detection of TNFcc. </p><p id="p0054" num="0054"> To detect TNFcc secretion by macrophages when stimulated by tumor cells after treatments, macrophages were incubated with treated tumor cells in 24-well tissue culture plates. After 24 hours of incubation, the supernatants were collected for ELISA detection. 
<!-- EPO <DP n="15"/>-->
 Animal Tumor Model. </p><p id="p0055" num="0055"> EMT6 cells (l x l O<sup>6</sup>) in a 0.1 -ml solution were injected into the flank region of female Balb/c mice, aged 6-8 weeks. Animals were used in experiments 7 to 10 days after tumor cell inoculation, when the tumors reached a size of approximately 300mm . </p><p id="p0056" num="0056"> Treatment of Animal Tumors Using Laser+SWNT-GC. </p><p id="p0057" num="0057"> Tumor-bearing mice were divided into different treatment groups (12-16 mice/group). A solution of 0.1-ml containing 5 mg/ml (25 mg/kg) GC or 0.2 mg/ml (1 mg/kg) SWNT or 0.2 mg-5 mg/ml (1 mg-25 mg/kg) SWNT-GC was directly injected into the center of each tumor, 2 hours before irradiation with a 980-nm laser. The light was delivered to the tumor using a fiber optic delivery system. The power density at the treatment area, which encompassed the tumor and 0.5 to 1 cm of the surrounding skin, was 0.75 W/cm<sup>2</sup> for a treatment duration of 10 minutes. During laser irradiation, mice were anesthetized with an intraperitoneal injection of pentobarbital sodium and were restrained in a specially designed holder. After treatment, the mice were observed daily and the tumors were measured every other day for a period of 100 days. </p><p id="p0058" num="0058"> Adoptive Immunity Transfer. </p><p id="p0059" num="0059"> Mice successfully treated by Laser+SWNT-GC and Laser+SWNT were challenged with an increased tumor dose of 2x 10<sup>6</sup> cells per mouse. At the same time, control mice of the same age were inoculated with the same number of tumor cells. Twenty-eight days after the tumor inoculation, the mice were terminated by cervical dislocation, and their spleens were dissected free of fat. Spleen cell suspensions were prepared by mechanical disruption into medium with 10% FCS. Spleen cells and viable tumor cells were counted on a hemocytometer before admixed. The admixture had a 500: 1 spleen to tumor cell ratio. Naive 
<!-- EPO <DP n="16"/>-->
 mice were inoculated with a 0.2-ml admixture containing 5x 10 spleen cells and 10 tumor cells. </p><p id="p0060" num="0060"> Seven days after treatment with different combinations of laser, SWNT, and GC, splenocytes from treated mice were cultured in the presence of EMT6 tumor cells for 5 days, after which cell cytotoxicity was assessed with CCK8. </p><p id="p0061" num="0061"> RESULTS </p><p id="p0062" num="0062"> Characterization of SWNT-GC. </p><p id="p0063" num="0063"> A stable SWNT-GC suspension was obtained after the final centrifugation of the solution. The schematic of SWNT-GC is given in Figure 1A. The near infrared absorption spectra of SWNT-GC exhibit a strong band around 980 nm (Figure IB), which is typical for CoMoCAT samples. The Roman spectra of SWNT-GC is given in Figure 1C. The optical absorbance of the GC solution in this spectral window is extremely low. </p><p id="p0064" num="0064"> The resonance ratio for the SWNT suspension in GC was measured to be 0.140, which favorably compares to NaCholate (with a similar ratio of 0.147), one of the best surfactants reported in literature. The SWNT-GC suspension remained stable after storage for more than six months at 4°C. </p><p id="p0065" num="0065"> Using SWNT-GC for light absorption enhancement, temperature increases at a depth of 4 mm below the surface of the gel phantom was measured by thermocouples. As shown in Figure 2A, a 12°C differential temperature increase was obtained between SWNT-GC enhanced gel and normal gel. The surface temperature increases of refrigerated samples are shown in Figure 2B. Under the same conditions, these increases demonstrate the selectivity of SWNT-GC at 980 nm. The temperature increase of the target sample can be controlled by adjustment of the SWNT-GC concentration and laser settings. 
<!-- EPO <DP n="17"/>-->
 The temperature distributions inside a normal gel block, before and during laser irradiation, obtained by magnetic resonance thermometry, are shown in Figures 3A and 3B. The temperature distribution inside the SWNT-GC enhanced gel block, before and during laser irradiation, are shown in Figures 3C and 3D. The results show a higher temperature increase in the SWNT-GC enhanced target. </p><p id="p0066" num="0066"> To confirm that SWNT could carry GC into tumor cells, SWNT-GC was functionalized with FITC, a fluorescent tag, and the fluorescence emission from the tumor cell incubated with SWNT-GC-FITC or GC-FITC was observed. Confocal images of the EMT6 cells show that SWNT-GC-FITC accumulates mainly in the cytoplasm, while GC- FITC is absent inside the cells (Figure 4). </p><p id="p0067" num="0067"> These results indicate that, as a unique quasi one-dimensional material, SWNT can carry GC into tumor cells, which fulfilled a crucial step for temporally and spatially synchronized photothermal and immunological reactions in the target tumor cells under laser irradiation. </p><p id="p0068" num="0068"> To determine the cytotoxicity of SWNT-GC under laser irradiation, EMT6 tumor cells were incubated with the SWNT-GC solution for 2 hours, followed by irradiation with a 980- nm laser. Tumor cytotoxicity depended on both the SWNT-GC concentration and the laser dose (Figure 5). </p><p id="p0069" num="0069"> In Vitro Immune Stimulation of SWNT-GC. </p><p id="p0070" num="0070"> Immunological observations showed that GC and SWNT-GC stimulated a similar level of TNFoc secretion at a given concentration, when incubated with murine macrophages, and the level of TNFcc secretion increased with GC concentration (Figure 6A). These results showed that the stable SWNT-GC suspension retained the immunological capability of GC. 
<!-- EPO <DP n="18"/>-->
 To determine the immunological responses induced by treated tumor cells, ELISA was performed to measure TNFa secreted by macrophages incubated with tumor cells after different treatments for 24 hours. As shown in Figure 6B, tumor cells incubated with either GC or SWNT-GC could stimulate a certain level of TNFa secretion, whereas a low dose laser irradiation (60 J/cm ) alone did not enhance the activation of macrophages. Tumor cells treated by higher doses of laser irradiation (120 or 150 J/cm<sup>2</sup>) also stimulated TNFa secretion by macrophages, due to laser induced cell death. However, at these high light doses, tumor cells treated by Laser+SWNT-GC resulted in much higher levels of TNFa secretion (Figure 6B). </p><p id="p0071" num="0071"> In Vivo Effects of SWNT-GC. </p><p id="p0072" num="0072"> EMT6 cells were injected subcutaneously in the flank of Balb/c female mice. After the tumor size reached approximately 300mm<sup>3</sup>, the animals were divided into eight different treatment groups. After treatment, the mice were observed daily and the tumor volume was measured using a caliper every other day. The mice treated by injections of SWNT (1 mg/kg, in PEG), GC (25 mg/kg), or SWNT-GC (1 mg-25 mg/kg) had an average tumor burden similar to that of untreated control mice (Figure 7A); none of the mice in these three groups exhibited tumor regression. In contrast, mice treated by laser irradiation (0.75W/cm for 10 min) had an average tumor burden noticeably smaller than that of the control mice (Figure 7B). Laser+SWNT and Laser+SWNT-GC treatments resulted in significant tumor suppression (Figure 7B). </p><p id="p0073" num="0073"> For survival studies, sixteen mice were used per each treatment group and the mice were monitored for 100 days after tumor inoculation. Among mice treated by a single injection of SWNT, GC, or SWNT-GC solution, there were no long-term survivors, although mice in GC and SWNT-GC groups had a slightly longer average survival time (Figure 8A). 
<!-- EPO <DP n="19"/>-->
 Under laser irradiation at a power density of 0.75W/cm<sup>2</sup>, the survival rates were 100% in the Laser+SWNT-GC group, 56% in the Laser+SWNT group, 38% in the Laser+GC group, and 25% in the Laser only group, respectively (Figure 8B). Nine of the sixteen mice in the Laser+SWNT group survived, but complete tumor regression was observed in only three mice, while no complete tumor regression was observed in the Laser+GC or the Laser only groups. Overall, the results in Figure 8 demonstrate that the Laser+SWNT-GC combination is the most efficacious treatment, resulting in a much higher survival rate and stronger tumor suppression than other combinations of laser, S WNT, and GC. </p><p id="p0074" num="0074"> Rechallenge of the Cured Mice. </p><p id="p0075" num="0075"> Mice successfully treated by Laser+SWNT-GC and Laser+SWNT were challenged with 2x l0<sup>6</sup> viable tumor cells 100 days after the initial tumor inoculation (10 mice per group). Ten naive mice of the same age were inoculated with 2 l0<sup>6</sup> viable tumor cells per mouse as controls. As shown in Figure 9, all the Laser+SWNT-GC cured mice showed total resistance to the challenge. However, all the Laser+SWNT cured mice developed primary tumors and died within 80 days of tumor re-challenge. All the control mice developed primary tumors and died within 40 days of tumor inoculation. The Laser+SWNT-GC cured mice were challenged a second time with an increased tumor dose (3x l0<sup>6</sup>/mouse). Again, they were completely refractory to the tumor rechallenge. </p><p id="p0076" num="0076"> Adoptive Immunity Transfer. </p><p id="p0077" num="0077"> Spleen cells from mice successfully treated by Laser+SWNT-GC or Laser+SWNT were harvested as immune cells. As controls, spleen cells from untreated tumor-bearing mice were also collected. The spleen cells were admixed with viable tumor cells at a ratio of 500: 1. Naive mice were inoculated by 10 viable tumor cells with 5x 10 spleen cells harvested from mice of different treatment groups. Figure 10 shows the survival rates of mice 
<!-- EPO <DP n="20"/>-->
 inoculated with the mixture of spleen cells and tumor cells. The spleen cells from Laser+SWNT-GC cured mice provided 100% protection to the recipients, while the spleen cells from Laser+SWNT cured mice protected only 30% of the recipients. The spleen cells from control tumor-bearing mice provided only 10% protection to the recipients (FigURE 10). Sixty days after adoptive immunity transfer, all the mice protected by the spleen cells from Laser+SWNT-GC-cured mice were challenged again with 2&gt;&lt; 10<sup>6</sup> tumor cells; all mice withstood the second challenge. </p><p id="p0078" num="0078"> DISCUSSION </p><p id="p0079" num="0079"> The ideal treatment modality for cancer, particularly metastatic cancer, should achieve a systemic, tumor-specific immunological response through a minimally invasive, local intervention. Such an approach could potentially suppress local tumors and at the same time eradicate metastases at distant sites, while providing anti-tumor immunity to the host with minimal adverse side effects. Photothermal reaction using lasers is an ideal local intervention due to its precise energy delivery to target tissue and the sensitivity of tumor tissue to temperature increase. </p><p id="p0080" num="0080"> Laser light in the NIR region, in combination with appropriate light-absorbing agents, is particularly attractive for selective photothermal interaction, because of the low absorbance of biological tissue in the NIR region. </p><p id="p0081" num="0081"> SWNTs have been used as therapeutic targets to induce thermal injury to cancer cells. It has been shown that death of cancer cells with internalized SWNTs could be induced by exposure to either continuous NIR light or radiofrequency radiation. </p><p id="p0082" num="0082"> Anti-tumor immune response can be significantly enhanced by introducing immunological stimulants to the tumors, particularly when combined with other interventions. When used appropriately, such immunostimulants can significantly improve 
<!-- EPO <DP n="21"/>-->
 the efficacy of cancer treatment by stimulating the host immune system, such as when Corynebacterium parvum, bacille Calmette-Gue'rin, or other immunoadjuvants were intratumorally administered in conjunction with phototherapy treatment. </p><p id="p0083" num="0083"> SWNTs by Co oCAT method are uniform in size and have a strong absorption peak around 980 nm, hence an ideal light-absorbing agent for the desired selective photothermal interaction in local intervention. The selective photothermal laser-tissue interaction using the 980-nm laser and CoMoCAT SWNT has been demonstrated through in vitro and in vivo experiments. </p><p id="p0084" num="0084"> GC has also been used previously as an immunoadjuvant for cancer treatment in animal studies. The purpose of the proposed novel SWNT-GC system is to further improve the laser immunotherapy. The molecular structures of CoMoCAT SWNTs and GC allow a stable, uniform SWNT suspension using GC as an effective surfactant (Figurel). The experimental results clearly show that the SWNT-GC solution retained the optical properties of SWNT (Figures 2 and 3) and the immunological properties of GC. </p><p id="p0085" num="0085"> The combination of SWNT-GC due to the electrical structure of both SWNT and GC also provides this novel system a unique advantage: carrying GC into the tumor cells. Usually, immunological stimulants like glycated chitosan, a long-chain polymer, cannot enter cells directly, as evidenced by the experimental results (Figure 4, top panel). SWNT has shown a capability to enter cells and localize in different subcellular components depending on the molecules SWNT is carrying. When GC is conjugated with SWNT, it can be carried into tumor cells (Figure 4, bottom panel). GC inside tumor cells can serve as exogenous immunological stimulant, hence further enhancing the immune responses induced by the combined photothermal and immunological reactions by laser+SWNT-GC. 
<!-- EPO <DP n="22"/>-->
 The advantage of the SWNT-GC system lies in its simultaneous, synergistic photothermal and immunological reactions during tumor treatment. Specifically, SWNT selectively absorbs the 980-nm laser light to induce tumor cell destruction, hence providing an exogenous cellular stress and tumor immunogen to the host. In addition, GC enhances the immune response at the same photothermal treatment site due to its conjugation with SWNT. Therefore, because of the unique bound of SWNT and GC, they can target the same tumor cell at the same time, resulting in synergistic photothermal and immunological reactions. </p><p id="p0086" num="0086"> The in vitro and in vivo results demonstrated the effectiveness of Laser+S WNT-GC in the treatment of animal tumors. </p><p id="p0087" num="0087"> While GC or SWNT-GC alone did not cause tumor cell death in vitro, combining with laser irradiation, particularly at higher doses (120 and 150 J/cm<sup>2</sup>), they could significantly increase cytotoxicity (Figure 5). Similarly, Laser+SWNT-GC treated tumor cells could induce much higher levels of TNFa secretion from macrophages, as shown by the data in Figure 6. These results demonstrate the synergistic effect of laser irradiation, light absorption of SWNT, and immunological stimulation of GC. </p><p id="p0088" num="0088"> The synergy between laser, SWNT, and GC was further demonstrated by in vivo experimental results, as shown in Figure 7. Intratumoral injections of SWNT, GC, or SWNT-GC did not result in tumor regression (Figure 7A), although treatments using single components with GC (GC or SWNT-GC) prolonged the medium survival time of the mice (Figure 8A). These results could be attributed to the nonspecific immune response of host, induced by GC, to enhance the tumor resistance, although such a response could not selectively destroy tumor cells, as evidenced by both in vitro (Figure 5) and in vivo (Figure 7A) results. When laser irradiation was used, the effect of SWNT-GC was significantly enhanced, both in vitro (Figure 5) and in vivo (Figure 7B). The treatment of Laser+SWNT- 
<!-- EPO <DP n="23"/>-->
 GC resulted in complete tumor suppression, while the treatment of Laser+SWNT also resulted in significant tumor suppression (Figure 7B). Specifically, with a laser power density 0.75 W/cm<sup>2</sup> and irradiation duration of 10 minutes, the Laser+SWNT-GC achieved a 100% cure rate, much higher than the cure rate of 56% with the Laser+SWNT treatment (Figure 8B). </p><p id="p0089" num="0089"> Mice successfully treated by Laser+SWNT-GC withstood subsequent challenges with increased tumor dose; all the cured mice in this group showed total resistance to the tumor rechallenge (Figure 9). However, the mice successfully treated with the Laser+SWNT all developed primary tumors and died about 80 days after the tumor rechallenge (Figure 9). These results demonstrate the essential role of GC in inducing long-lasting anti -tumor immunity. </p><p id="p0090" num="0090"> Splenocytes from mice cured by Laser+SWNT-GC provided 100% protection to normal recipient mice when the animals were injected with a mixture of the spleen cells and tumor cells, as shown in Figure 10. In comparison, splenocytes from mice cured by Laser+SWNT only provided partial protection to the recipient mice (Figure 10). These results indicate that Laser+SWNT-GC induced a long-term memory in immune cells, again, attributed to the effect of GC. </p><p id="p0091" num="0091"> It is hypothesized that the mechanism of Laser+SWNT-GC in the treatment of tumors lies in the synergistic reactions between the selective photothermal reaction and immunological stimulation. The photothermal reaction reduces the tumor burden and at the same time exposes the tumor antigens; the immunoadjuvant in situ first stimulates the host immune system and then directs the immune system against the specific tumor cells. In each individual host, in fact, laser immunotherapy produced an in situ auto vaccine. This tandem effect not only resulted in total tumor eradication but also led to a long-term tumor-specific 
<!-- EPO <DP n="24"/>-->
 immunity. This method, therefore, provides a systemic immunotherapy through local intervention for each individual host without the usually required immune cross-reactivity. </p><p id="p0092" num="0092"> In the present disclosure, an immunoadjuvant has been used as a surfactant to effectively disperse nanotubes to provide synergistic photothermal and immunological effects under laser irradiation. This system of the disclosure, due to its unique optical properties and immunological functions, could be used in the treatment of tumors, particularly metastatic tumors. The system of the invention, due to the strong binding of SWNT and GC, allowed GC being carried into the tumor cells, further enhancing the photothermal and immunological effects of laser+SWNT-GC. </p><p id="p0093" num="0093"> In summary, selective photothermal interaction and tumor-specific immunological stimulation provided by Laser+SWNT-GC, which simultaneously target the tumor cells spatially and temporally, are contemplated for use as an effective cancer treatment therapy. </p><p id="p0094" num="0094"> * * * * </p><p id="p0095" num="0095">Thus, the present invention is well adapted to carry out the objectives and attain the ends and advantages mentioned above as well as those inherent therein. While presently preferred embodiments have been described for purposes of this disclosure, numerous changes and modifications will be apparent to those of ordinary skill in the art. 
</p></description><claims mxw-id="PCLM44851948" ref-ucid="WO-2012118857-A2" lang="EN" load-source="patent-office"><claim id="clm-0001" num="0001"><!-- EPO <DP n="25"/>--><claim-text/><claim-text>CLAIMS </claim-text><claim-text>1. A method of photoimmunological therapy for inducing tumor cell destruction and anti-tumor immune responses comprising: </claim-text><claim-text> internalizing nanostructures, for use as a light-absorbing agent, in a body of the tumor cell in a host; </claim-text><claim-text> exposing said cell body to either continuous near-infrared light or to radiofrequency radiation for providing an exogenous cellular thermal damage or stress, thereby leading to death of the tumor cell and exposure of said tumor cell to tumor antigens. </claim-text><claim-text>2. The method according to claim 1 wherein: </claim-text><claim-text> said nanostructures are modified with an immunological stimulant. </claim-text><claim-text>3. The method according to claim 2 wherein: </claim-text><claim-text> said immunological stimulant is glycated chitosan. </claim-text><claim-text>4. The method according to claim 1 further comprising: </claim-text><claim-text> intratumorally administering, to said tumor cells, immunological stimulant conjugated to said nanostructures, said immunological stimulant selected from a group consisting of corynebacterium partum, bacill Calmette-Gue'rin, or other immunoadj uvants ; </claim-text><claim-text> wherein said nanostructures are singled-walled carbon nanotubes. 
<!-- EPO <DP n="26"/>-->
 The method according to claim 1 further comprising: </claim-text><claim-text> intratumorally administering, to said tumor cells, immunological stimulant conjugated to said nanostructures selected from a group comprising nanoparticles, nanoclusters, and nanorods, said immunological stimulant selected from a group consisting of corynebacterium partum, bacill Calmette-Gue'rin, or other immuno adj uvant s . </claim-text><claim-text>The method according to claim 5 wherein: </claim-text><claim-text> said nanoparticles, nanoclusters, and nanorods are comprised of gold. </claim-text><claim-text>The method according to claim 1 wherein: </claim-text><claim-text> said nanostructures have a strong absorption peak in a range of 700 to 1500 nm. </claim-text><claim-text>The method according to claim 7 wherein: </claim-text><claim-text> said nanostructures have a strong absorption peak with a wavelength having a range of 800 to 1200 nm. </claim-text><claim-text>The method according to claim 1 wherein: </claim-text><claim-text> said near-infrared light is produced by a 980-nm laser. 
<!-- EPO <DP n="27"/>-->
 The method according to claim 9 wherein: </claim-text><claim-text> said near-infrared light is produced by a laser having a laser power density in the ranges of 0.1 to 5 W/cm , and administered with an irradiating duration of 5 to 60 minutes. </claim-text><claim-text>The method according to claim 10 wherein: </claim-text><claim-text> said near-infrared light is produced by a laser with a power density of 0.75 to 2</claim-text><claim-text>W/cm<sup>2</sup>. </claim-text><claim-text>The method according to claim 10 wherein: </claim-text><claim-text> said near-infrared light is administered with an irradiating duration of 10 to 30 minutes. </claim-text><claim-text>A composition comprising: </claim-text><claim-text> nanostructures dissolved in an aqueous solution of glycated chitosan; </claim-text><claim-text> whereby said glycated chitosan is a surfactant for rendering said aqueous solution stable; and </claim-text><claim-text> wherein said glycated chitosan is an immunostimulant. </claim-text><claim-text>The composition according to claim 13 wherein: </claim-text><claim-text> said nanostructures are singled-walled carbon nanotubes. </claim-text><claim-text>The composition according to claim 13 wherein: </claim-text><claim-text> said nanostructures are modified with an immunological stimulant. 
<!-- EPO <DP n="28"/>-->
</claim-text><claim-text>16. The composition according to claim 13 wherein: </claim-text><claim-text> said nanostructures have a strong absorption peak in the range of 800 to 1200 nm. </claim-text><claim-text>17. An immunologically active compound comprising: </claim-text><claim-text> a nanostructure coated with glycated chitosan molecules. </claim-text><claim-text>18. The immunologically active compound according to claim 17 wherein: </claim-text><claim-text> said nanostructure is a singled-walled carbon nanotube. </claim-text><claim-text>19. The immunologically active compound according to claim 17 wherein: </claim-text><claim-text> said nanostructure is modified with an immunological stimulant. 20. The immunologically active compound according to claim 17 wherein: </claim-text><claim-text> said nanostructure has a strong absorption peak in the range of 800 to 1200 nm. </claim-text><claim-text>21. A method of delivering an immunostimulant to a cell body and of producing targeted, synergistic photophysical and immunological reactions comprising: </claim-text><claim-text> coating a nanostructure with glycated chitosan; </claim-text><claim-text> penetrating a cell membrane of a cell body with said nanostructure. 
<!-- EPO <DP n="29"/>-->
</claim-text><claim-text>22. The method according to claim 21 wherein: </claim-text><claim-text> said nanostructure is a singled-walled carbon nanotube. </claim-text><claim-text>23. The method according to claim 21 further comprising the step of: </claim-text><claim-text> irradiating said nanostructure after said step of penetrating. </claim-text><claim-text>The method according to claim 23 wherein: </claim-text><claim-text> said step of irradiating includes exposing said cell body with near-infrared light for facilitating synergistic, simultaneous photothermal and immunological reactions. </claim-text><claim-text>The method according to claim 24 wherein: </claim-text><claim-text> said near-infrared light is produced by a 980-nm laser. </claim-text><claim-text>The method according to claim 25 wherein: </claim-text><claim-text> said laser has a laser power density of 0.75 to 2 W/cm; and </claim-text><claim-text> said step of irradiating comprises administering said laser with an irradiating duration of 10 to 30 minutes. </claim-text><claim-text>The method according to claim 23 wherein: </claim-text><claim-text> said step of irradiating includes exposing said cell body with radiofrequency radiation for facilitating synergistic, simultaneous photothermal and immunological reactions. 
<!-- EPO <DP n="30"/>-->
</claim-text><claim-text>29. The method according to claim 21 further comprising the step of: </claim-text><claim-text> modifying said nanostructure with an immunostimulant. </claim-text><claim-text>30. The method according to claim 21 wherein: </claim-text><claim-text> said nanostructure has a strong absorption peak in the range of 800 to 1200 nm. </claim-text><claim-text>31. A method of making a composition of singled- walled carbon nanotube/glycated chitosan comprising: preparing an aqueous solution of glycated chitosan; </claim-text><claim-text> mixing singled-walled carbon nanotubes into said aqueous solution to form a mixture; </claim-text><claim-text> sonicating said mixture to disperse said singled-walled carbon nanotubes; centrifuging said mixture; </claim-text><claim-text> comparing an optical absorbance of said mixture with an optical absorbance of a calibration mixture of a known concentration for determining a concentration of said singled-walled carbon nanotubes in said mixture. </claim-text><claim-text>32. The method according to claim 31 wherein: said singled-walled carbon nanotubes are produced by catalytic decomposition of Co on bimetallic Co-Mo catalysts. 
<!-- EPO <DP n="31"/>-->
 The method according to claim 31 wherein: said step of mixing utilizes approximately 2.5 to 2.7 mg of said singled-walled carbon nanotubes mixed with approximately 7 mL of said aqueous solution glycated chitosan. 
</claim-text></claim></claims><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
